China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the Center for Drug Evaluation (CDE) for its investigational lyophilized human rabies vaccine (serum-free Vero cells). This approval marks a significant step forward in the company’s efforts to develop and commercialize innovative rabies vaccines.
Vero Cells and Vaccine Development
Vero cells, known for their sensitivity to viruses, are capable of cultivating virus strains with high titer. These cells can be produced on a large scale through continuous passage, maintaining high stability. AIM Vaccine has already commercialized a human rabies vaccine using Vero cells, achieving market dominance in this area, according to the announcement.
Future Vaccine Pipeline
Looking ahead, AIM Vaccine plans to launch three rabies vaccines for human use, all of which are investigational. These include vaccines based on serum-free Vero cells, mRNA, and human diploid cells. The company expects to introduce these vaccines into the market in or after 2025, positioning itself at the forefront of rabies vaccine innovation.
Future Outlook
The clinical trial approval for the serum-free Vero cell rabies vaccine underscores AIM Vaccine’s commitment to advancing its vaccine pipeline. With multiple innovative rabies vaccines in development, the company aims to address the ongoing need for effective and accessible rabies prevention solutions.-Fineline Info & Tech
